Enliven Therapeutics, Inc. (ELVN) SEC Filings — 2024
26 SEC filings for Enliven Therapeutics, Inc. (ELVN) in 2024.
Filings
- Enliven Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- Enliven Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- Enliven Therapeutics, Inc. SC 13G Filing — SC 13G · Nov 13, 2024
- Enliven Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 13, 2024
- Enliven Therapeutics, Inc. SC 13G Filing — SC 13G · Nov 8, 2024
- Enliven Therapeutics, Inc. SC 13G Filing — SC 13G · Oct 24, 2024
- Enliven Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024
- 5AM Ventures VI Amends Enliven Therapeutics Stake — SC 13D/A · Jul 29, 2024
- Enliven Therapeutics Files 8-K on Governance and Officer Changes — 8-K · Jun 18, 2024
- Enliven Therapeutics Files 8-K/A Amendment — 8-K/A · May 29, 2024
- OrbiMed Amends Stake in Enliven Therapeutics — SC 13D/A · May 20, 2024
- Enliven Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024
- Enliven Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders on June 18 — DEF 14A · Apr 26, 2024
- 5AM Ventures VI amends Enliven Therapeutics stake — SC 13D/A · Apr 15, 2024
- Enliven Therapeutics Files 8-K — 8-K · Apr 11, 2024
- Enliven Therapeutics Files 8-K on Director/Officer Changes — 8-K · Apr 9, 2024
- OrbiMed Amends Enliven Therapeutics Stake — SC 13D/A · Apr 4, 2024
- Enliven Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 19, 2024
- Enliven Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 14, 2024
- 5AM Ventures Amends Enliven Therapeutics Stake — SC 13D/A · Feb 16, 2024
- Enliven Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Enliven Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Enliven Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- FMR LLC & Abigail Johnson Maintain 14.321% Stake in Enliven Therapeutics — SC 13G/A · Feb 9, 2024
- BML Investment Partners Amends Enliven Therapeutics Stake — SC 13G/A · Feb 7, 2024
- 5AM Ventures Reduces Enliven Therapeutics Stake to 16.7% — SC 13D/A · Feb 2, 2024